Barclays raised the firm’s price target on Agilent to $135 from $125 and keeps an Underweight rating on the shares. The analyst says Q1 is shaping up to be a rather inconsequential “do nothing” quarter for the life science tools and diagnostics space. The firm does not expect to get a lot of data one way or the other on many of the bull/bear debates. It believes investors continue to favor bioprocessing names broadly over instrument-focused companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
